|
|
|
|
|
|
|
|
|
|
video (7:47 min)
Dr. Haffizulla: Thank you for joining us for this PracticeUpdate. I’m Dr. Farzanna Haffizulla. I am here with Dr. Axel Grothey. Dr. Grothey is a consultant in the Division of Medical Oncology at the Mayo Clinic. He’s also a professor of oncology in clinical and translational science. Again, we’re so happy to have you here today.
Dr. Grothey: Thank you for having me.
Dr. Haffizulla: How are new technologies, such as circulating tumor DNA–based assays, changing the way we consider primary and secondary drug-resistance mechanisms?....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.